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Abstract 
Background: The advent of immune checkpoint inhibitors (ICIs) has considerably expanded the armamentarium 
against non-small cell lung cancer (NSCLC) contributing to reshaping treatment paradigms in the advanced disease 
setting. While promising tissue- and plasma-based biomarkers are under investigation, no reliable predictive factor is 
currently available to aid in treatment selection.
Methods: Patients with stage IIIB–IV NSCLC receiving nivolumab at Sant’Andrea Hospital and Regina Elena National 
Cancer Institute from June 2016 to July 2017 were enrolled onto this study. Major clinicopathological parameters were 
retrieved and correlated with patients’ survival outcomes in order to assess their prognostic value and build a useful 
tool to assist in the decision making process.
Results: A total of 102 patients were included in this study. The median age was 69 years (range 44–85 years), 69 
(68%) were male and 52% had ECOG PS 0. Loco-regional/distant lymph nodes were the most commonly involved site 
of metastasis (71%), followed by lung parenchyma (67%) and bone (26%). Overall survival (OS) in the whole patients’ 
population was 83.6%, 63.2% and 46.9% at 3, 6 and 12 months, respectively; while progression-free survival (PFS) was 
66.5%, 44.4% and 26.4% at 3, 6 and 12 months, respectively. At univariate analysis, age ≥ 69 years (P = 0.057), ECOG PS 
(P < 0.001), the presence of liver (P < 0.001), lung (P = 0.017) metastases, lymph nodes only involvement (P = 0.0145) 
were significantly associated with OS and ECOG PS (P < 0.001) and liver metastases (P < 0.001), retained statistical 
significance at multivariate analysis. A prognostic nomogram based on three variables (liver and lung metastases and 
ECOG PS) was built to assign survival probability at 3, 6, and 12 months after nivolumab treatment commencement.
Conclusion: We developed a nomogram based on easily available and inexpensive clinical factors showing a good 
performance in predicting individual OS probability among NSCLC patients treated with nivolumab. This prognostic 
device could be valuable to clinicians in more accurately driving treatment decision in daily practice as well as enroll-
ment onto clinical trials.
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Background
Lung cancer represents a massive health burden world-
wide with 1.7 million deaths annually and a 26% increase 
in incidence during the last decade [1]. More than a half 
of patients present with stage IV disease and less than 5% 
of them survive beyond 5 years [2].
The introduction of immune checkpoint inhibitors 
(ICI) has considerably expanded the armamentarium 
against non-small cell lung cancer (NSCLC) contribut-
ing to reshaping treatment paradigms in the advanced 
disease setting [3, 4]. The anti-PD-1 pembrolizumab both 
as monotherapy and combined with platinum/peme-
trexed doublet is considered a first-line treatment option 
in PD-L1 overexpressing (≥ 50%) [5] and unselected 
patients [6], respectively, in absence of actionable onco-
genic drivers. Moreover, the anti-PD-L1 atezolizumab 
has emerged as a further front-line therapeutic choice 
both in combination with bevacizumab, carboplatin and 
paclitaxel [7] and platinum-based doublets [8] in NSCLC 
regardless of PD-L1 status. In the second-line setting, 
nivolumab [9] and atezolizumab [10] (irrespective of 
PD-L1 expression) and pembrolizumab (PD-L1 ≥ 1%) 
[11] are approved as single-agent for chemotherapy pre-
treated, immunotherapy-naïve patients.
The fast-growing number of immunotherapeutics and 
their limited efficacy with 70–80% of patients progress-
ing within the first 2–3  months underline the need for 
predictive biomarkers aiding in treatment selection [12]. 
Moreover, a subset of patients termed as hyperprogres-
sors and ranging from 9 to 29% have been described that 
experience a paradoxically accelerated tumour growth 
while on ICI treatment [13]. Tumour-associated mac-
rophages reprogramming towards a pro-tumorigenic 
phenotype upon Fc receptor engagement by ICI has been 
suggested to have a causative role in this phenomenon in 
patients with distinctive immune and genetic profiles.
Nivolumab is a fully human IgG4 anti-PD1 monoclonal 
antibody that showed to prolong OS compared to doc-
etaxel in NSCLC failing first-line chemotherapy. How-
ever, it yielded a response rate as low as 13.6% to 23% and 
a median PFS of 2.3 to 4 months in biomarker-unselected 
patients [9, 10]. Several biomarkers are being studied 
that can help to enrich for patients more likely to ben-
efit from nivolumab [14, 15]. PD-L1 is a suboptimal pre-
dictive biomarker since less than 50% of PD-L1-selected 
patients respond to treatment and some responders may 
be encountered also in ‘biomarker-negative’ cohorts. 
Tumour mutational burden (TMB) holds great promise 
and up to now is the sole clinically validated biomarker. 
Nevertheless, no consensus exists on how it should be 
measured and its widespread use is thus limited. Addi-
tional promising tissue- and plasma-based predictive 
biomarkers are under investigation, including tumour 
infiltrating lymphocytes, “immunoscore” (composite 
biomarker integrating four T cell related IHC features), 
immune gene signatures, eosinophil, lymphocyte and 
neutrophil counts and relative ratios from peripheral 
blood, plasma IL-6 and IDO, microsatellite instability 
status, interferon signature, T cell repertoire, MHC sta-
tus and microbiome profile [14]. Among clinical factors, 
poor performance status (ECOG PS ≥ 2), a period of time 
since prior treatment ≥ 6  months and involvement of 
more than one metastatic site have been independently 
associated with shorter OS in a cohort of 175 pretreated 
NSCLC patients receiving nivolumab [16]. More recently, 
ECOG PS ≥ 2, liver and lung metastases have been sug-
gested to be independent predictors of nivolumab effi-
cacy in an Asian population of 201 advanced NSCLC 
[17].
The aim of our study is to assess the predictive-prog-
nostic significance of clinicopathological parameters in 
NSCLC patients receiving second-line nivolumab treat-
ment in clinical practice in order to build a useful tool to 
assist in the decision making process.
Materials and methods
Patients
Patients with stage IIIB-IV NSCLC receiving nivolumab 
at Sant’Andrea Hospital and Regina Elena National Can-
cer Institute from June 2016 to July 2017 were enrolled 
onto this study. Inclusion criteria were: age > 18  years; 
histologically-documented diagnosis of NSCLC; East-
ern Cooperative Oncology Group (ECOG) performance 
status ≤ 2; measurable disease; progression on or after 
first-line platinum-containing doublet; patients harbor-
ing oncogenic driver aberrations (i.e. EGFR mutations 
or ALK fusion oncogene) were required to have received 
previous tyrosine kinase inhibitor therapy; adequate car-
diac, pulmonary, renal, liver and bone marrow function; 
patients with stable and asymptomatic central nervous 
system metastases were eligible. Exclusion criteria were: 
autoimmune disease; symptomatic interstitial lung dis-
ease and any other significant comorbidity; systemic 
immunosuppression; prior treatment with immune-stim-
ulatory antitumor agents including checkpoint-targeted 
agents. All patients gave written informed consent.
The study was conducted in accordance with good 
clinical practice guidelines and the declaration of Hel-
sinki. The final version of the protocol was approved by 
the Institutional Ethics Committee of the two Institutions 
involved.
Treatment, efficacy and safety assessments
Nivolumab was administered intravenously at a stand-
ard dose of 3 mg/kg every 2 weeks until disease progres-
sion or development of unacceptable toxicity. Tumour 
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response was assessed at week 9 and every 6 weeks there-
after until disease progression using immune-related 
Response Evaluation Criteria in Solid Tumors Criteria 
(i-RECIST) and classified according to disease control 
(complete response, partial response and stable disease) 
and progressive disease. Safety assessments were per-
formed at day 1 of every cycle until the end of treatment 
and toxicities were graded according to the National 
Cancer Institute Common Terminology Criteria for 
Adverse Events (version 4.0).
Objectives and outcomes
Progression-free survival (PFS) was defined as the time 
from nivolumab commencement until the first docu-
mented tumour progression or death from any cause, 
whichever occurred first. Overall survival (OS) was 
defined as the time from nivolumab commencement to 
death from any cause.
Early progressors patients were defined as those expe-
riencing disease progression within 3  months from the 
beginning of nivolumab treatment.
The association between early progression and clin-
icopathological factor PS, age, sex and site of metasta-
ses was assessed together with the association between 
PFS > 12 months and PS, age, sex and site of metastases.
Statistical analysis
Categorical variables are presented as a number with a 
percentage in descriptive tables, and they were compared 
with Fisher’s exact test or Pearson’s Chi-square test. The 
impact of clinicopathological variables on overall survival 
(OS) and progression-free survival (PFS) was analyzed by 
both the univariate and multivariate analyses (UVA and 
MVA, respectively). With regards to UVA, patients’ OS 
and PFS were analyzed using the Kaplan–Meier method 
and log-rank tests. Prognostic clinic-pathological varia-
bles deemed of potential relevance in the univariate anal-
ysis (corresponding to a cutoff of P < 0.10) were included 
in the multivariate Cox proportional hazards regression 
analysis. A nomogram to predict 3, 6, and 12-months 
survival probability was developed based on covariates 
retaining a statistically significant power (P < 0.05) in 
MVA. To quantify the discrimination performance of the 
nomogram, Harrell’s C-index was measured. The nomo-
gram was subjected to bootstrapping validation (1000 
bootstrap resamples) to calculate a relatively corrected 
C-index. Calibration was studied graphically after group-
ing patients into deciles with respect to their predicted 
probabilities and plotting the mean predicted prob-
abilities against the mean observed probabilities. Boot-
strapping was applied to correct the model based on the 
estimated optimism. Internal validation was performed 
determining the OS in each calculated group. Discrimi-
nation of nomogram was tested by Kaplan–Meier curves 
and boxplots. A P < 0.05 was considered statistically 
significant. Statistical analyses were performed using 
R-package software.
Results
Patients
A total of 102 patients fulfilled the inclusion criteria and 
were enrolled in this study. Overall, the median age was 
69 years (range 44–85 years), Sixty-nine (68%) were male 
and 52% had ECOG PS 0. Loco-regional/distant lymph 
nodes were the most commonly involved site of metas-
tasis (71%), followed by lung parenchyma (67%) and bone 
(26%). Other baseline clinicopathological parameters are 
reported in Table  1. Seventy-two (88%) patients experi-
enced early progression, while seven (39%) patients pre-
sented PFS longer than 12 months.
After a median follow-up period of 11  months (range 
1–29  months), all 102 treated patients were assessable 
for OS. At the time of the analysis, 55 (54%) patients 
had died. OS in the whole patients’ population was 
83.6%, 63.2% and 46.9% at 3, 6 and 12  months, respec-
tively; while PFS was 66.5%, 44.4% and 26.4% at 3,6 and 
12 months, respectively.
Prognostic factors, nomogram development 
and performance
The OS was significantly shorter in patients 
aged > 69  years old compared to those younger than 
69  years old. Patients with liver metastases (Figs.  1, 2) 
experienced a significantly lower OS, while those affected 
by lung metastatic deposits lived longer.
At UVA assuming the cutoff of P < 0.10 for include 
potential interest parameters, age ≥ 69  years (P = 0.057), 
ECOG PS (P < 0.001), the presence of liver (P < 0.001), 
lung (P = 0.017) metastases, lymph nodes only involve-
ment (P = 0.0145) were significantly associated with OS 
and were included in the multivariate analysis. ECOG PS 
(P < 0.001) and liver metastases (P < 0.001), retained sta-
tistical significance at MVA (Tables  2, 3). Based on the 
estimated regression coefficients in the Cox analysis, a 
prognostic nomogram that included liver, lung metasta-
ses and ECOG PS was developed to assign survival prob-
ability at 3, 6, and 12 months after nivolumab treatment 
commencement (Fig. 3).
To use the nomogram, a vertical line needs to be delin-
eated to the point raw to assign point values for each 
variable. Thereafter, the corresponding points are to be 
summed to obtain the total points. Finally, from the total 
points a vertical line needs to be drawn to get the value 
of 3, 6, 12 months OS probability. The presence of lung 
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metastases corresponds to 20 points, the presence of liver 
metastases corresponds to 0 points, while the ECOG PS 
of 1 corresponds to 50 points. The total point of 70 cor-
responds a 3- and 6-month OS of about 0.6 (60%) and 0.3 
(30%), respectively.
The C-indexes for OS models was 0.76 and calibra-
tion of the nomogram for OS was considered adequate 
(Fig. 4). Kaplan–Meier curves according to the range of 
total points highlighted the appropriateness of distin-
guish the patients’ survival in all the subgroups (Fig. 5). 
The groups were obtained considering the total point 
distribution of our population. Group I and II (red lines) 
represent patients with poor outcome.
The PFS was significantly shorter in patients with 
liver metastases (P < 0.0001) and higher ECOG PS score 
(P < 0.0001), while was longer in patients having only 
lung lymph nodes (P = 0.0017) and lung metastases 
(P = 0.0443). ECOG PS (P < 0.001) and liver metastases 
(P < 0.001) resulted statistically significant at MVA. The 
C-indexes for PFS models was 0.72.
Table 1 Baseline clinico-pathological characteristics (n = 102)
Parameter N (%)
Age years (median, range) 69 (44–85)
Height 168 cm (152–186)
Weight 69.5 kg (45–175)
Gender
 Male 69 (68%)
 Female 33 (32%)
ECOG PS
 0 53 (52%)
 1 41 (40%)
 2 8 (8%)
Lung parenchyma metastasis
 Yes 68 (67%)
 No 34 (34%)
Lymph node metastasis
 Yes 72 (71%)
 No 30 (29%)
Loco-regional lymph node metastasis
 Yes 31 (30%)
 No 71 (70%)
Liver metastasis
 Yes 19 (19%)
 No 83 (81%)
Brain metastasis
 Yes 14 (14%)
 No 88 (86%)
Malignant pleural effusion
 Yes 9 (9%)
 No 93 (91%)
Bone metastasis
 Yes 27 (26%)
 No 75 (74%)
Adrenal gland metastasis
 Yes 11 (11%)
 No 91 (89%)
N. of metastatic sites
 1 21 (21%)
 2 34 (33%)
 3 47 (46%)
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Fig. 2 PFS according to liver metastases status
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Discussion
In the last few years, an unprecedented number of immu-
notherapeutics including the anti-PD1 nivolumab have 
proven effective compared to standard chemotherapy 
in pretreated NSCLC patients that has greatly expanded 
treatment options beyond first-line. However, in spite of 
a proportion of them deriving a long-term disease con-
trol, roughly 60–80% of patients progress on ICI carrying 
a dismal prognosis [18]. Hence, the question on how to 
properly select the best candidates to second-line immu-
notherapy has rapidly risen and represents thus an urgent 
unmet need.
Table 2 Univariate and multivariate analysis for OS
Italic values refer to statistically significant covariates (p value < 0.05) for OS
Covariate Univariate analysis Multivariate analysis
HR (95% CI) P value HR (95% CI) P value
Age ≥ 69 years 0.6389 (0.3691–1.1060) 0.057 – –
Sex 1.4 (0.7892–2.485) 0.247 – –
Weight ≥ 69.5 kg 1.1999 (0.6606–2.1794) 0.543 – –
Height > 168 cm 0.9492 (0.4884–1.8445) 0.876 – –
Liver metastasis 3.6912 (2.0123–6.7710) 0.000 3.0637 (1.6693–.623) 0.0003
Lung metastasis 0.4954 (0.2858–0.8587) 0.017 0.6209 (0.3564–1.082 0.0925
Lymph node metastasis 0.4954 (0.2858–0.8587) 0.2723 – –
Only lymph node metastasis 0.4482 (0.2363–0.8502) 0.0145 – –
Brain metastasis 0.9460 (0.4728–1.8927) 0.876 – –
Malignant pleural effusion 0.991 – –
Bone metastasis 1.4029 (0.8022–2.4535) 0.2375 – –
Adrenal gland metastasis 1.1271 (0.5095–2.4933) 0.7689 – –
N. of metastatic sites 1.1610 (0.7966–1.6921) 0.4395 – –
ECOG PS 2.706 (1.774–4.126) < 0.0001 2.588 (1.655–4.046) < 0.0001
Line of treatment 1.1507 (0.7571–1.7488) 0.5133 – –
Global < 0.0001
Table 3 Univariate and multivariate analysis for PFS
Italic values refer to statistically significant covariates (p value < 0.05) for PFS
Covariate Univariate analysis Multivariate analysis
HR (95% CI) P value HR (95% CI) P value
Age (≥ 69 years) 0.7437 (0.4732–1.1688) 0.2015 – –
Sex 1.313 (0.8109 -2.126) 0.268 – –
Weight (≥ 69.5 kg) 1.1089 (0.6850–1.7950) 0.6756 – –
Height (> 168 cm) 1.0502 (0.6274–1.7577) 0.8530 – –
Liver metastasis 2.9391 (1.6952–5.0957) 0.0001 3.456 (2.002–5.965) < 0.0001
Lung metastasis 0.6133 (0.3818–0.9852) 0.0443 – –
Lymph node metastasis 0.7610 (0.4697–1.2330) 0.2697 – –
Only Lymph node metastasis 0.4324 (0.2567–0.7282) 0.0017 – –
Brain metastasis 1.0419 (0.5639–1.9251) 0.8964 – –
Malignant pleural effusion 1.0225 (0.4452–2.3485) 0.9583 – –
Bone metastasis 1.5459 (0.9538–2.5057) 0.0786 – –
Adrenal gland metastasis 1.2286 (0.6145–2.4563) 0.5623 – –
N. of metastatic sites 1.1524 (0.8550–1.5533) 0.3542 – –
ECOG PS 2.26 (1.602–3.187) < 0.0001 2.260 (1.580–3.233) < 0.0001
Line of treatment 1.0253 (0.7140–1.4724) 0.8928 – –
Global < 0.0001
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Of interest, some reports have proposed clinical prog-
nostic factors in advanced-stage NSCLC treated with 
second-line nivolumab, among which is ECOG PS.
Our findings concerning the impact of patients’ gen-
eral health conditions on nivolumab efficacy are aligned 
with those previously described in the literature. Indeed, 
poor ECOG PS (≥ 2) has been consistently shown to be 
Fig. 3 Prognostic nomogram for NSCLC patients to assign their probability of survival at 3, 6, and 12-months after nivolumab treatment initiation. 
The probability of survival at 3, 6, and 12 months can be obtained as function of total points calculated as the sum of points for each specific 
variable. Points are assigned for each risk factor by drawing a line upward from the corresponding values to the ‘point’ line. The total sum of points 
for three risk factors is plotted on the ‘total points’ line. A line is drawn down to read the corresponding predictions of 3-, 6-, 12-month-survival 
probability
Fig. 4 Calibration plot of the final nomogram for OS. All patients were grouped based on their predicted probabilities. Mean predicted probabilities 
were plotted against the actual incidence of PFS. The reference line represents perfect quality of observed frequencies and predicted probabilities
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an independent predictor of poorer survival in both clini-
cal trials and real-life experience of nivolumab-treated 
patients [19–21]. With regards to the role of age, at the 
UVA, we found that elderly patients (> 70 years) were less 
likely than younger to benefit from nivolumab. Limited 
and conflicting data are available regarding the safety 
and efficacy of nivolumab in older people due to their 
underrepresentation in clinical trials and the lack of ran-
domized studies in this specific subset of patients.
Among disease characteristics in our cohort, lung 
and lymph nodes metastases seemed to be favourable 
prognostic factors, while liver involvement emerged 
as a negative feature. Accordingly, a growing number 
of studies have been suggesting that ICI treatment may 
have a differential outcome based on the type of meta-
static involvement. In particular, liver metastases have 
been independently associated with poorer survival in 
the real-world setting [16, 17]. Likewise, the updated 
follow-up of CheckMate 017 and CheckMate 057 dem-
onstrated in the experimental arm 3-year OS of 8% vs. 
17% in patients with liver metastases compared to the 
whole population [18]. Consistently, a cohort from Key-
note 001 evaluating another anti-PD1 pembrolizumab 
confirmed a reduced response rate (28.6% vs. 56.7%) and 
shortened PFS in NSCLC patients with liver metastasis 
(mPFS 1.8 vs. 4 months, P = 0.0094), compared to those 
without liver metastasis [22]. To this end, accumulating 
preclinical evidence is shedding light on the differential 
response and clinical benefit seen with anti-PD1 agents 
according to metastatic sites and specifically on the 
poorer prognosis of patients with liver metastases.
It was demonstrated that liver metastases seem to 
be “colder” than a primary tumour or lung and lymph 
node metastases [23]. In addition, in the liver micro-
environment, T cells have been shown to interact with 
sinusoidal endothelial cells, resulting in differentiation 
of the T cells into a Treg phenotype and/or in partial 
activation of the T cells, followed by passive cell death 
[24]. More interestingly, circulating levels of Eotaxin-2 
and IP-10 that are chemokines attracting immunosup-
pressive immune cells have been reported to be higher 
in patients with liver metastatic involvement from 
both melanoma and colorectal cancer, further pointing 
toward unique immunosuppressive mechanisms sus-
tained by liver metastases.
In the present study, we investigated the role of clinical 
features in order to build a nomogram enabling individu-
alized OS estimation in a real-world cohort of advanced 
NSCLC receiving the anti-PD1 agent nivolumab as sec-
ond- or later line of treatment. The prognostic nomo-
gram is based on readily available, inexpensive and 
easily-to-collect patient (ECOG PS) and disease variables 
(liver and lung metastases).
The present study has some limitations to be acknowl-
edged. This is a retrospective bicentric cohort study with 
a 11-month follow up and a relatively small sample size, 
thereby with potential for inherent biases. Still, the lack 
of data regarding PD-L1 expression determined by using 
the Tumor Proportion Score is another shortcoming of 
the analysis. Finally, external prospective validation is 
required to assess reproducibility and generalizability of 
our results.
Conclusion
We developed an easy-to-use and inexpensive device 
to assist the clinician with a quantitative tool to predict 
OS probability in NSCLC treated with nivolumab in the 
clinical practice. The nomogram was built on the basis of 
clinico-pathological variables which retained independ-
ent prognostic value in the MVA and showed an ade-
quate performance. While waiting for novel biomarkers, 
this prognostic tool could be valuable to more accurately 
driving treatment decision in daily practice and enroll-
ment onto clinical trials.
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